KIT在子宫肉瘤的表达及临床意义

KIT expression in uterine sarcoma and its clinical significance

目的:研究用甲磺酸伊马替尼治疗子宫肉瘤的可能性。方法:使用免疫组化的方法分析30例甲醛固定石蜡包埋的子宫肉瘤KIT的表达。结果:使用半定量免疫组化计分发现在所有检验的子宫肉瘤中只有1例KIT表达,而且较微弱,而被检验的子宫肉瘤中没有表现出很强的表达。结论:目前的资料表明甲磺酸伊马替尼不可能作为单一有效的药物对子宫肉瘤使用。

Objective：To investigate the possibility of treating uterine sarcomas with imatinib mesylate.Methods：Expression of KIT was analyzed immunohistochemically（n=30） in formalin-fixed paraffin-embedded uterine sarcomas.Results：Used a semi-quantitative immunohistochemical score we found only 1 case of uterine sarcomas express used KIT,and relatively weak.While none of the uterine sarcoma tested showed strong expression.Conclusion：The current data suggest that it is unlikely that imatinib mesylate could be used effectively as a single agent in patients with uterine sarcoma.